+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-04-01Number of Pages: 91

Opioid Induced Constipation Treatment Market: (Mu-opioid Receptor Antagonist, Chloride Channel Activator, and Others; Solid, Semi-solid, and Liquid): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023


1. Preface
     1.1. Report Description
     1.2. Research Methodology
     1.3. Market Segmentation

2. Executive Summary
     2.1. Market Snapshot

3. Opioid Induced Constipation Treatment Market - Industry Analysis
     3.1. Introduction
     3.2. Event Impact Analysis 
     3.3. Pain 
     3.4. Market Dynamics
            3.4.1. Drivers
            3.4.2. Restraints
            3.4.3. Opportunities
     3.5. Regulatory Scenario
     3.6. Competitive Landscape
3.6.1. Market Share Analysis of Key Players, 2014 (Value %)
     3.7. Market Attractiveness Analysis of Global Opioid Induced Constipation Treatment Market, by Geography, 2014 

4. Market Segmentation - By Dosage Form of the Drug 
     4.1. Introduction 
     4.2. Global Solid Dosage Form Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.3. Global Semi-solid Dosage Form Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.4. Global Liquid Dosage Form Market Revenue, 2013–2023 (US$ Mn) and Analysis

5. Market Segmentation - By Drug Class
     5.1. Introduction 
     5.2. Global Mu Opioid Receptor Antagonist Market Revenue, 2013–2023 (US$ Mn) and Analysis
     5.3. Global Chloride Channel Activator Market Revenue, 2013–2023 (US$ Mn) and Analysis
     5.4. Global Others Market Revenue, 2013–2023 (US$ Mn) and Analysis

6. Pipeline Analysis
     6.1. Overview 
     6.2. Late Stage (Phase III) 
            6.2.1. Naldemedine
            6.2.2. Others
     6.3. Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)

7. Market Segmentation - By Geography
     7.1. Introduction
     7.2. Global Opioid Induced Constipation Treatment Market Revenue, by Region, 2013–2023 (US$ Mn)
     7.3. North America Opioid Induced Constipation Treatment Market Revenue, by Country, 2013–2023 (US$ Mn)
            7.3.1. U.S. Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.3.2. Canada Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
     7.4. Europe Opioid Induced Constipation Treatment Market – Revenue, by Country, 2013–2023 (US$ Mn)
            7.4.1. U.K. Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.4.2. Germany Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.4.3. France Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.4.4. Rest of Europe Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
     7.5. Asia Pacific Opioid Induced Constipation Treatment Market Revenue, by Country, 2013–2023 (US$ Mn)
            7.5.1. Australia Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.5.2. Japan Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.5.3. South Korea Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.5.4. Rest of APAC Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
     7.6. Latin America Opioid Induced Constipation Treatment Market Revenue, by Country, 2013–2023 (US$ Mn)
            7.6.1. Brazil Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.6.2. Rest of Latin America Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
     7.7. Rest of the World Opioid Induced Constipation Treatment Market Revenue, by Country, 2013–2023 (US$ Mn)

8. Recommendations

9. Company Profiles
     9.1. Abbott Laboratories, Inc.
     9.2. AstraZeneca plc
     9.3. Bayer AG
     9.4. Boehringer Ingelheim GmbH
     9.5. C.B. Fleet Company, Inc.
     9.6. COSMO Pharmaceuticals
     9.7. Daewoong Pharmaceutical Co. Ltd. 
     9.8. Takeda Pharmaceutical Co., Ltd.
     9.9. Valeant Pharmaceuticals International, Inc. 


 
 
Back To Top